Dr. Reddy's Labs

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.

Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug

Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.

Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates

Dr. Reddy's Laboratories Ltd (RDY) CEO Gunupati Prasad on Q4 2019 Results - Earnings Call Transcript

Dr. Reddy's Laboratories reported its quarterly earnings results, which topped expectations, yet RDY stock declined more than 1% today.

Dr. Reddy’s Laboratories Earnings: RDY Stock Dips Despite Q4 Beat

Dr. Reddy's earnings and sales increase year over year in the fourth quarter of fiscal 2019.

Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat

Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.

Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?

Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.

Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs

News for Dr. Reddy's Labs Stock (RDY)